APPENDIX III 
Informed Consent 
Informed Consent 
University of Illinois at Chicago 
College of Medicine 
Specialized Cancer Center 
840 South Wood Street (M/C 820) 
Chicago, Illinois 60612 
Protocol Title: Pilot Study of Toxicity of Immunization of Patients 
with Unresectable Melanoma with IL-2-Secreting Allogeneic Human 
Melanoma Cells 
PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH 
1. PARTICIPANT'S NAME 
I . D . NUMBER 
You are being asked to participate in a clinical research study. The doctors 
at the University of Illinois at Chicago (UIC) study the nature of disease and 
attempt to develop improved methods of diagnosis and treatment. This is 
called clinical research. In order to decide whether or not you should agree 
to be part of this research study, you should understand enough about its 
risks and benefits to make an informed judgment. This process is known as 
informed consent. 
This consent form gives detailed information about the research study which 
the doctor will discuss with you. Once you understand the study, you will be 
asked to sign this form if you wish to participate. You will have a copy to 
keep as a record. 
The title of the proposed research study is: 
"Pilot Study of Toxicity of Immunization of Patients with Unresectable 
Melanoma with IL-2-Secreting Allogeneic Human Melanoma Cells" 
2 . PURPOSE OF THE RESEARCH STUDY 
Treatment of patients with metastatic melanoma has been disappointing. In a 
very small number of patients, the cancer has disappeared without treatment. 
This suggests that an individual patient's immune system might be stimulated 
in such a way that makes it capable of fighting the cancer. For these 
reasons, new treatments that can increase an individual's immune response 
against his/her melanoma are being investigated. The purpose of this study is 
to evaluate the toxicity of injecting patients such as yourself with melanoma 
cells from another patient that have been modified genetically. 
[366] 
Recombinant DNA Research, Volume 18 
